Food antihypertensive peptides by Pascual Fabregat, Guillem & Universitat Autònoma de Barcelona. Facultat de Veterinària
FOOD ANTIHYPERTENSIVE PEPTIDES
Guillem Pascual Fabregat
INTRODUCTION
Bioactive peptides are encrypted within the primary of food proteins where they remain inactive until
realise by hydrolysis. Antihypertensive peptides are those peptides which have the ability to modulate
the activity of the enzymes and receptors that regulate human blood pressure. They could modulate the
renin-angiotensin system (RAS) and other pathways like arginine-nitric oxide system.
This project focuses on describing the main peptides and protein hydrolisates production methods and
their subsequent in vitro and in vivo activity essays. Also, it describes which molecular targets such ACE
inhibits and how. And, finally, it classifies hypotensive peptides according to their protein source.
METHODOLOGY 
➢ Bibliographic search of reviews and research articles in
databases.
➢ Reading and abstracting the collected literature in order to
elaborate the written review.
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FROM PROTEIN SUBSTRATE TO COMERCIAL PRODUCTS
HYPERTENSION PHISIOPHATOLGY & PEPTIDES ACTION MECHANISMS
FOOD SCIENCE                     
& TECNOLOGY
THE RENIN-ANGIOTENSINE SYSTEM & ARGINE-NITRIC OXIDE SYSTEM PAHTWAYS ACE INHIBITION
The primary structure of peptides is a relevant factor to search potentially ACE
inhibitors. Statistical modelling plus in vitro essays are used to identify the
active peptides sequence with peptides databases help.
The results obtained for ACE-inhibitors are:
BBCAAs like Valine & Isoleucine
AAAs like Phenylalanine, Tryptophan
C-terminal Proline
* Wu et al., & Sagardia et al. reveal the importance of C-terminal sequence.
C2 (aa +)
C4 (Trp)
CONCLUSIONS
There are multitude of different antihypertensive peptides. Those hypotensive peptides could be
classified according to their natural source (e.g. milk), their production method (e.g. enzymatic
hydrolysis), the molecular targets that they modulate (e.g. ACE) or the correspondent activity assays
to evaluate their antihypertensive potential (e.g. SHR).
Also, one key is their bioavailability. Some of they are not available to be absorbed by intestinal
epithelium, or they could be digested by endogens enzymes and become inactive.
FUTURE PRESPECTIVES
Anyway, antihypertensive peptides are a suitable tool to
reduce the blood pressure. In the near future they could
substituted synthetics drugs. For now, more research,
concerning the structural requirements for modulating the
biological targets is needed. As well as humans essays that
demonstrate the healthy properties of peptides reducing the
incidence of hypertension.
Examples of antihypertensive peptides depending on molecular targets
-Collagen hydrosilate inhibits competitively. (1)
-Egg albumen peptides from lysozyme inhibits
no competitively. (2)
Pea protein hydrosilate studied with SHR
model and human. (3)
Egg pentapeptide (RVPSL) reduce mRNA
expression. (4)
Egg peptide (Arg-Val-Pro-Ser-Leu) reduce
renal AT-II renal RNAm expression. (4)
Lactoferrin milk peptide block AT-II. (5)
Amarant glutenin digested by tripsin induce
NO production. (6)
The population ingest an average of 50-70 g of protein per day. Some of
antihypertensive peptides had been found intrinsically in natural
products, such as fermented food like tofu or cured meats. The most
studied food groups are milk and eggs, but recently scientists have been
studying another kind of animal and vegetable proteins.
➢ Chemic hydrolysis: Use of acid and alkali solutions. Bad specificity.
➢ Enzymatic hydrolysis: Use of proteases and peptidases (optimal Tª& pH).
Enzyme cleavage is very important to originate bioactive peptides.
➢ Microbial fermentation: During the fermentation, some bacteria and
yeast secrete exoproteases that digest food proteins.
➢ Recombinant DNA technology: Genetic recombination is used to achieved
DNA which will express a novel mRNA, translating a novel protein.
Emerging methodology.
Before commercialisation of
novel products is necessary
exhaustive investigations to
prove the antihypertensive
effects in humans and the
minimum doses needed.
In vitro
The reduced or potentiated activity
of a enzyme involved in blood
pressure modulation could be
estimated by different methods,
like spectrophotometry, HPLC or
fluorometry.
PROTEIN SOURCE PROTEIN HYDROLIS
COMERCIAL PRODUCT ASSAY TESTING
In vivo
Consist on proving the
antihypertensive peptides effects, like
the measure of systolic and diastolic
blood pressure, in spontaneous
hypertensive rats modelling (SHR).
Fig. 1. Blood Pressure Regulation
Fig. 2.  ACE inhibitors action mechanism 
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